Opinion: STAT+: Market share isn’t the only metric for biosimilars’ success
Market share is often held up as the most relevant metric for the success of a biosimilar class. I believe there are other metrics, like cost savings or signs of greater patient access, that should...
View ArticleVirtual Event: Biosimilars’ Meteoric Moment
Editor’s note: A recording of the event is embedded below. Like approaching asteroids, major biosimilars for Humira and other drugs are finally due to hit the market in 2023.Read the rest…
View ArticleOpinion: STAT+: Removing barriers to biosimilar adoption in the United States
Biosimilars, a much-lauded approach to reducing drug costs in the United States, are still underused here, even as they are proving successful in Europe. Why? Two key reasons are misperceptions of...
View ArticleSTAT+: ‘Skinny labels’ on biosimilar medicines saved Medicare $1.5 billion...
A hotly contested provision of a federal law designed to speed copycat drugs to market and foster competition saved Medicare $1.5 billion from 2015 to 2020 — or nearly 5% of the $30.2 billion spent by...
View ArticleOpinion: To protect the medical supply chain, ‘made in America’ will be key
The Covid-19 pandemic exposed a serious flaw in the United States’ medical supply chain: an overreliance on imported supplies. Reinvigorating a domestic supply chain is an important step toward...
View ArticleOpinion: STAT+: A watershed year for biosimilars — if regulators and...
January 31 is set to mark the start of a watershed year for the biosimilars industry with the release of Amjevita, the first biosimilar for Humira, the world’s best-selling drug. Several more Humira...
View ArticleSTAT+: Amgen pricing for its Humira biosimilar may benefit PBMs and insurers...
Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited discounts for its biosimilar version of Humira — the world’s best-selling medicine — and the numbers...
View ArticleSTAT+: Watch: Blockbuster drug Humira has new competition. Here’s why that...
Humira has been the world’s best-selling medicine since it arrived on the market in 2002. Now, it is finally getting competition with the release of Amgen’s biosimilar drug, Amjevita. Humira’s main...
View ArticleSTAT+: Supreme Court rules against Amgen in closely watched case over scope...
In a case that had the pharmaceutical industry on edge, the U.S. Supreme Court upheld a lower court ruling that Amgen failed to disclose sufficient information about patent claims for a best-selling...
View ArticleSTAT+: Coherus works with Mark Cuban to sell biosimilar Humira at steep...
In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira — one of the world’s best-selling medicines — at a steep discount, and will work with Mark Cuban’s generic drug company...
View ArticleSTAT+: Pharmalittle: PBMs are targeted in yet another congressional bill;...
Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, given the clear and sunny skies — and delicious breezes — enveloping the Pharmalot campus...
View ArticleSTAT+: Pharmalittle: Eisai executive to retire; Express Scripts adds three...
Top of the morning to you, and a fine one it is. Birds are chirping and cool breezes are wafting by the Pharmalot campus, where the official mascots are racing about the grounds. As for us, we are...
View ArticleSTAT+: STAT Virtual Event: The State of Biosimilars: What to Watch
Editor’s note: A recording of the event is embedded below. Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can...
View ArticleOpinion: STAT+: The problem with potential changes to the biosimilar...
Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation...
View ArticleOpinion: STAT+: A year in, the U.S. is still not taking advantage of...
It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved...
View ArticleOpinion: STAT readers on what human health care can learn from veterinary...
STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here, or...
View ArticleSTAT+: Here’s what you might have missed in Biden’s budget proposal
WASHINGTON — President Biden on Monday unveiled his requests for the 2025 budget, potentially his last chance to cement a legacy on drug costs, cancer research, and broad health care coverage. The...
View ArticleClik here to view.
STAT+: Virtual Event: March of the Biosimilars
Editor’s note: A recording of the event is embedded below. Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year....
View ArticleSTAT+: Boehringer Ingelheim layoffs are a sign of dysfunctional Humira...
WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less-expensive...
View ArticleSTAT+: Thanks to CVS, a biosimilar version of AbbVie’s Humira is grabbing...
The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment, one of the best-selling medicines in the U.S., surged to 36% from just 5% during the first...
View Article